Shots:
- Genevant is eligible to receive ~$303M up front and milestone along with royalties on future product sales
- Takeda gets exclusive rights to use Genevant’s LNP technology for the development and commercialization of specified nonviral gene therapies for up to two undisclosed rare liver diseases
- The collaboration follows the initial 2021 agreement in which companies collaborated to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis
Click here to read full press release/ article | Ref: Genevant Sciences | Image: Genevant Sciences
The post Takeda Signs a License Agreement with Genevant to Develop and Commercialize Novel Nonviral Gene Therapies for Liver Diseases first appeared on PharmaShots.
